Antimesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination

Checkpoint immunotherapy is a major breakthrough for cancer treatment, yet its efficacy is often limited against many types of malignancies, including malignant mesothelioma. Considering that the immunotherapeutic efficacy depends on immunosurveillance, we sought to develop an active immunization me...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Zhiwu, Chiu, Mei Sum, Yan, Chi Wing, Wong, Yik Chun, Huang, Haode, Man, Kwan, Chen, Zhiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068049/
https://www.ncbi.nlm.nih.gov/pubmed/32195318
http://dx.doi.org/10.1016/j.omto.2020.01.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068049/
https://www.ncbi.nlm.nih.gov/pubmed/32195318
http://dx.doi.org/10.1016/j.omto.2020.01.009

Ejemplares similares